Seres therapeutics reports first quarter 2022 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “seres continued to make important progress toward bringing ser-109 to patients suffering with recurrent c. difficile infection (rcdi). given the robust profile of ser-109 observed in our phase 3 study, we expect the product to have a significant impact on rcdi, a serious disease with approximate
MCRB Ratings Summary
MCRB Quant Ranking